NRx Pharmaceuticals’ (NRXP) “Buy” Rating Reaffirmed at D. Boral Capital

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reiterated by investment analysts at D. Boral Capital in a research note issued to investors on Monday,Benzinga reports. They currently have a $31.00 price objective on the stock.

Several other equities analysts have also issued reports on the company. Ascendiant Capital Markets raised their price target on NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd. HC Wainwright restated a “buy” rating and issued a $19.00 price target on shares of NRx Pharmaceuticals in a research note on Thursday.

NRx Pharmaceuticals Price Performance

Shares of NASDAQ:NRXP traded down $0.07 during trading on Monday, hitting $2.02. 75,476 shares of the company were exchanged, compared to its average volume of 451,673. NRx Pharmaceuticals has a 52-week low of $1.10 and a 52-week high of $6.01. The company has a market cap of $34.09 million, a PE ratio of -0.94 and a beta of 1.22. The stock has a 50 day moving average of $2.82 and a 200 day moving average of $2.03.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its earnings results on Friday, March 14th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.10). Sell-side analysts forecast that NRx Pharmaceuticals will post -1.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in NRXP. Townsquare Capital LLC purchased a new position in NRx Pharmaceuticals in the 3rd quarter worth approximately $25,000. Sassicaia Capital Advisers LLC bought a new stake in shares of NRx Pharmaceuticals in the 4th quarter worth $33,000. Squarepoint Ops LLC purchased a new position in shares of NRx Pharmaceuticals in the fourth quarter worth $56,000. Millennium Management LLC bought a new position in shares of NRx Pharmaceuticals during the fourth quarter valued at $61,000. Finally, Anson Funds Management LP purchased a new stake in shares of NRx Pharmaceuticals during the third quarter valued at $241,000. Institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.